ÇÝÀàIgY¿¹ÌåÔÚÕï¶Ï¡¢ÖÎÁÆÖеÄÓ¦ÓÃ
ÇÝÀ࿹ÌåÔÚÉúÃü¿ÆѧÓëҽѧÁìÓòÖеÄÓ¦ÓÃÔ½À´Ô½Êܵ½¹Ø×¢¡£ÓÉÓÚÇÝÀàÓ벸È鶯ÎïϵͳµÄÒÅ´«¾àÀë¡¢¿¹Ìå¶àÑù»¯µÄ»úÖÆÒÔ¼°IgYÔÚµ°»ÆÖгÁ»ýµÄ·½Ê½£¬Ê¹µÃÇÝÀàÌرðÊǼ¦×÷ΪÃâÒßËÞÖ÷¾ßÓÐÐí¶àÓÅÊÆ¡£Ê×ÏÈ£¬ÇÝÀàÓ벸È鶯Îï¼äµÄÒÅ´«¾àÀë½ÏÔ¶£¬¶Ô²¸È鶯ÎïÔ´µÄ¿¹ÔÎïÖÊÈÝÒײúÉúÇ¿ÃâÒßÓ¦´ð£¬ÇÒ¿ÉÒÔÕë¶Ô¸ü¶à²¸È鶯ÎԱíλÐγɿ¹Ìå¡£Æä´Î£¬IgY¾ßÓнÏÇ¿µÄÄÍÈÈ¡¢ÄÍËá¡¢Ä͸ßÉøÐÔÄÜÒÔ¼°Ò»¶¨µÄ¿¹Ã¸½âÄÜÁ¦£¬Õâ¿ÉÄÜÊÇIgYÖØÁ´É϶îÍâµÄ¶þÁò¼üÌṩÁ˸ü¸ßµÄ·Ö×ÓÎȶ¨ÐÔ¡£CDR3ÇøÊǾö¶¨½áºÏ¿¹ÌåÇ׺ÍÁ¦ºÍÌØÒìÐÔµÄÖ÷µ¼ÇøÓò¡£ÓëIgGÏà±È£¬IgYÖØÁ´CDR3²Ð»ùÊý¸ü¶à£¬ÕâʹµÃIgYµÄÇ׺ÍÁ¦ºÍÌØÒìÐÔ¸üºÃ¡£×îÖØÒªµÄÊÇ£¬IgYµÄFcÇø²»Ó벸È鶯ÎïµÄFcÊÜÌå¡¢Àà·çʪÒò×Ó£¨RF£©¡¢CF£¨ÓÈÆäÊÇC1qºÍC3£©ÒÔ¼°µ°°×A¡¢µ°°×G¡¢µ°°×L·¢ÉúÏ໥×÷Ó㬿ÉÒÔ±ÜÃâÃâÒß·ÖÎöÖеÄÏÔÖø¸ÉÈźͽ»²æ·´Ó¦¡£»ùÓÚÒÔÉÏÓÅÊÆ£¬ÇÝÀàIgY¿¹Ì忪ʼ¹ã·ºÔËÓÃÓÚÃâÒßÕï¶Ï»òÖÎÁÆÐÔ¿¹ÌåÒ©ÎïµÄ¿ª·¢¡£
IgYÔÚÃâÒßÕï¶ÏÖеÄÓ¦ÓÃ
ÔÚÃâÒß¼ì²âÖУ¬Ñù±¾ÖдæÔÚµÄÄÚÔ´ÐÔ¸ÉÈÅÎïÖÊ£¬ÈçÒìÊÈÐÔ¿¹Ì壨HA£©¡¢ÈË¿¹¶¯ÎÌ壨HAAA£©ºÍÀà·çʪÒò×Ó£¨RF£©»áͨ¹ýÓ뿹ÌåµÄ·ÇÌØÒìÐÔ½áºÏ£¬½µµÍ¼ì²âµÄÁéÃô¶ÈºÍÌØÒìÐÔ£¬µ¼Ö¼ÙÑôÐÔ»ò¼ÙÒõÐÔ½á¹û¡£´ËÍ⣬ͨ¹ý¿¹ÌåFcÊÜÌå»òÄý¼¯Ëصķǿ¹ÔÒÀÀµÐÔÌØÒìÐÔ½áºÏ»òÆäËû»ùÓÚ·ÇÃâÒßÇòµ°°×µÄÏ໥×÷Óã¬ÈçÓɲ¹ÌåÒò×ӽ鵼µÄÏ໥×÷Óã¬Ò²¿ÉÄܵ¼Ö¼ì²â½á¹ûµÄÆ«ÆÄ¡£¾Ýͳ¼Æ£¬ÒìÊÈÐÔ¿¹Ìå¶Ô¼ì²â½á¹ûµÄ¸ÉÈű仯·¶Î§´Ó1%ÖÁ80%¡£¶Ô³¬¹ý11000·Ý¼ì²âCEAµÄѪÇå½øÐиü³¹µ×µÄ·ÖÎöºó·¢ÏÖ£¬Ô¼4%µÄ¼ì²â½á¹û¿ÉÄÜÊÇ´íÎóµÄ¡£Ïû³ýÒìÊÈÐÔ¿¹Ìå¸ÉÈŵķ½·¨°üÀ¨È¥³ý×è¶Ï¸ÉÈÅÐÔ¿¹Ì壬Ȼ¶øʹÓÃÕâÀà·½·¨ÏëÒªÍêÈ«½â¾öÕâЩÎÊÌâµÄ¿ÉÄÜÐÔ²»´ó¡£
IgYµÄ×îÓÐȤÇÒ²»Ñ°³£µÄÌØÕ÷¾ÍÊÇFcÇø²»Ó벸È鶯ÎïµÄFcÊÜÌå¡¢Àà·çʪÒò×Ó£¨RF£©¡¢CF£¨ÓÈÆäÊÇC1qºÍC3£©ÒÔ¼°µ°°×A¡¢µ°°×G¡¢µ°°×L·¢ÉúÏ໥×÷Óá£ÕâʹµÃIgYÌرðÊʺÏÓ¦ÓÃÓÚÈÝÒײúÉú²»±ØÒª½»²æ·´Ó¦µÄ¼ì²â¡£ÈçÔÚÒ»Ïîµ°°×ÖÊ×éѧÑо¿ÖУ¬Ê¹ÓÃÌØÒìÐÔIgYÔ¤´¦ÀíѪÇåÑùÆ·£¬Öк͸߷á¶ÈѪÇå³É·Ö£¬¿ÉÒÔ¸ÄÉÆÏÂÓηÖÎö¡£ÔÚÁíÒ»ÏîÑо¿ÖУ¬Ê¹ÓÃÌØÒìÐÔIgY×÷Ϊ·â±ÕÊÔ¼Á£¬¼ò»¯Á˵ͷá¶ÈѪÇåµ°°×µÄ¼ì²âºÍ¼²²¡±êÖ¾ÎïºòÑ¡ÎïµÄ·¢ÏÖ¡£
±í1 IgYÔÚÃâÒßÕï¶ÏÖеÄÓÅÊÆ
|
²¸È鶯ÎïIgG |
ÇÝÀàIgY |
| Ö÷ÒªÀ´Ô´ |
Ѫ½¬ |
µ°»Æ |
| ²¸È鶯ÎԿ¹ÌåµÎ¶È |
ͨ³£½ÏµÍ |
ͨ³£½Ï¸ß |
| ÓëProtein A/Protein G ½áºÏ |
++++ |
¨C |
| Ó벸È鶯Îïϸ°ûFcÊÜÌå½áºÏ |
++++ |
¨C |
| ÃâÒ߸´ºÏÎＤ»î²¸È鶯Îï²¹Ìåϵͳ |
++++ |
¨C |
| ¿¹ÌåÉú²úÄÜÁ¦ |
90ÌìÃâÒß/50~70mLѪÇå 500~700 mg IgG |
90ÌìÃâÒß/60¸ö¼¦µ°
3-6 g IgY |
| Ó¦ÓÃ |
RIA¡¢IRMA¡¢ELISA¡¢Western blot¡¢FACSµÈ |
RIA¡¢IRMA¡¢ELISA¡¢Western blot¡¢FACSµÈ |
IgYÔÚÃâÒßÁÆ·¨ÖеÄÓ¦ÓÃ
ÇÝÀàºÍ²¸È鶯ÎïÖ®¼äµÄϵͳ·¢Óý¾àÀëÈ·±£ÁËÇÝÀà¶Ô²¸È鶯ÎïÔ´¿¹ÔµÄÇ¿ÃâÒß·´Ó¦¡£ÕâÖÖÌØÕ÷ÓÐÀûÓÚ²úÉúÕë¶Ô²¸È鶯ÎïÖ×Áö¿¹ÔµÄIgY¡£AmirijavidvµÈÈËÕë¶ÔTRAILÊÜÌåTRAIL-R2£¨DR5£©°ûÍâ¶ÎÉϵÄ21¸ö°±»ùËáÖƱ¸Á˸߶ÈÌØÒìÐÔµÄIgY¡£ÕâÖÖIgYÓëÊÜÌå°ûÍâëĶνáºÏºó£¬¼¤»îÈËÈéÏÙ°©Ï¸°ûMCF7ÖеÄDR5ÊÜÌ壬×÷ΪTRAIL¼¤¶¯¼ÁÓÕµ¼Ï¸°ûµòÍö¡£YANµÈͨ¹ý¹¹½¨°ÐÏòHER2µÄIgYÓëµ¥±Ú̼ÄÉÃ׹ܣ¨SWNT£©µÄżÁª¸´ºÏÎÔÚ±í´ïHER2µÄSK-BR-3ϸ°ûºÍHER2ÒõÐÔµÄMCF-7ϸ°ûµÄÌåÍâÄ£ÐÍÖÐÖ¤Ã÷Á˸ø´ºÏÎï¼ì²âºÍÑ¡ÔñÐÔÆÆ»µ°©Ï¸°ûµÄË«Öع¦ÄÜ¡£ÕâЩÑо¿±íÃ÷£¬Õë¶ÔÖ×Áö¿¹Ô²úÉúµÄIgYÊǸü¾ßÑ¡ÔñÐԵİ©Ö¢ÖÎÁÆÌæ´ú·½°¸¡£
IgYÔÚÇÝÐóÒß²¡·ÀÖÎÖеÄÓ¦ÓÃ
¿¹ÉúËØÔÚÑøÖ³ÒµÖÐÒ»Ö±ÓÃÓÚ´Ù½øÉú³¤£¨ÑÇÖÎÁƼÁÁ¿£©¡¢¼²²¡Ô¤·À£¨Ô¤·À¼ÁÁ¿£©ºÍÖÎÁƸÐȾ¡£ËÇÁÏÖп¹ÉúËصĹýÁ¿Ê¹ÓúÍÎóÓõ¼ÖÂÁ˶¯Îï²úÆ·ÖÐÒ©Îï²ÐÁôµÄÎÊÌâºÍÄÍÒ©ÐÔµÄÔö¼Ó¡£IgY×÷ΪһÖÖÔ¤·ÀºÍ¿ØÖÆÇÝÐó¼²²¡µÄÊÖ¶ÎÒýÆðÁËÏ൱µÄ¹Ø×¢¡£Ó벸È鶯ÎïIgGÖÎÁÆÏà±È£¬IgY°ÚÍÑÁËʹÓÿ¹Ìå¿Ú·þÃâÒßÁÆ·¨¼«¸ßµÄ³É±¾Ô¼Êø¡ª¡ªÄ¸¼¦¿ÉÒÔ¿´×÷ÊÇÉú²ú¿¹ÌåµÄСÐÍ¡°¹¤³§¡±£ºÒ»Ö»Ä¸¼¦Í¨³£Ã¿Äê²úÏÂÔ¼300¸ö¼¦µ°£¬Ã¿¸öµ°»Æº¬ÓÐ50-100mgµÄIgY£¬ÆäÖÐ2%ÖÁ10%ÊÇÌØÒìÐÔ¿¹Ìå¡£Òò´Ë£¬ÃâÒßһֻĸ¼¦Ã¿Äê¿É²úÉú³¬¹ý22500 mgµÄIgY£¬Ï൱ÓÚ4.3Ö»ÍÃ×ÓÒ»Äê²úÉú¿¹ÌåµÄÁ¿¡£ËÇÑøĸ¼¦µÄά»¤³É±¾Ò²µÍÓÚÍÃ×ӵȲ¸È鶯Îï¡£
IgYµÖÓù²¡ÔÌå»îÐԵĻúÖƸÅÊöÈçÏ£º
1.Äý¼¯
ʹÓÃIgY´¦Àíºó£¬¿ÉÒԹ۲쵽ϸ¾úÉú³¤»ò¶¨Ö²±»ÒÖÖÆ£¬ÕâÖÖ×÷Óò¢·ÇÊǶԵ¥¸öϸ¾úµÄÖ±½ÓÓ°Ï죬¶øÊÇÓÉÓÚIgYµÄÁ½¸öFab±ÛµÄ¿Õ¼äλ×裬×è°ÁËϸ¾úµÄ½»Áª£¬´Ó¶øµ¼ÖÂϸ¾úÄý¼¯¡£
2.ÒÖÖÆ𤸽
һЩÌåÍâÑо¿±íÃ÷£¬ÒÖÖÆ𤸽ÊÇÌØÒìÐÔIgYµÖÏû²¡ÔÌå»îÐÔµÄÖ÷Òª»úÖÆ¡£±©Â¶ÔÚ¸ïÀ¼ÊÏÒõÐÔ¾ú±íÃæµÄÌض¨³É·Ö£¬ÈçÍâĤµ°°×¡¢Ö¬¶àÌÇ¡¢¾úëºÍ±Þ룬ËüÃÇÊÇϸ¾ú¶¨Ö²µÄ¹Ø¼üÒòËØ£¬¿ÉÒÔ±»ÏàÓ¦µÄÌØÒìÐÔ¿¹Ìåʶ±ðºÍ½áºÏ¡£ÕâÖÖ½áºÏ¿ÉÄÜ»á×è¶Ï»òËðº¦Ï¸¾úÉú³¤Ïà¹Ø¹¦Äܵijɷ֣¬ÒÖÖÆϸ¾úÉú³¤¡£
3.µ÷ÀíºóÍÌÊÉ×÷ÓÃ
ÓÐÑо¿·¢ÏÖIgY¸ÄÉÆÁËÖÐÐÔÁ£Ï¸°û¶Ô½ð»ÆÉ«ÆÏÌÑÇò¾úµÄÍÌÊÉ×÷Óá£Óë´ËÀàËÆ£¬IgY´æÔÚµÄÇé¿öÏ£¬Èé¾ÞÊÉϸ°û»ò¶àÐκËÖÐÐÔÁ£Ï¸°û¶Ô´ó³¦¸Ë¾úµÄÍÌÊÉ»îÐÔÏÔ×ÅÔö¼Ó¡£ÕâЩ½á¹û±íÃ÷£¬IgYÔöÇ¿ÁËÍÌÊÉ»îÐÔ¡£Í¨¹ýÓëÌØÒìÐÔIgY½áºÏ£¬¹Û²ìµ½Ï¸¾ú±íÃæ½á¹¹¸Ä±ä£¬ÕâЩ±ä»¯¿ÉÒÔͨ¹ýϸ¾ú±íÃæµç×ÓÔƺÍ/»òµç³¡µÄ±ä»¯À´½âÊÍ£¬µ¼ÖÂϸ¾úϸ°û¸üÈÝÒ×Êܵ½ÍÌÊÉ×÷ÓõÄÓ°Ïì¡£
4.¶¾ËØÖкÍ
½ð»ÆÉ«ÆÏÌÑÇò¾ú¼ÔĤÊÇÒýÆðÅ£ÈéÏÙÑ×·¢×÷µÄÖØÒªÖ²¡¾úÖ®Ò»¡£IgY¿ÉÒÔ×èÖ¹ÈéÏÙÉÏƤϸ°û¶Ô½ð»ÆÉ«ÆÏÌÑÇò¾úµÄÄÚ»¯£¬Õâ±íÃ÷IgY¿ØÖÆÅ£ÈéÏÙÑ×µÄÖ÷Ҫ;¾¶ÎªÖкͶ¾ËØ»îÐÔ£¬¶ø²»ÊÇÖ±½ÓÒÖÖÆÉú³¤¡£
±í2 IgYÔÚÇÝÐóÒß²¡·ÀÖÎÖеÄÓ¦ÓÃ
| ²¡ÔÌåÃû³Æ |
IgYµÄ×÷Óà |
ÎÄÏ×À´Ô´ |
| ÂÖ×´²¡¶¾ |
Ô¤·ÀÅ£ÂÖ×´²¡¶¾ÒýÆðµÄ¶¿Å£¸¹Ðº |
Kuroki et al. (1994) |
| Ô¤·ÀÊóÂÖ×´²¡¶¾ |
Yolken et al. (1988) |
| Ô¤·ÀÈËÀàÂÖ×´²¡¶¾ÒýÆðµÄСÊó賦Ñ× |
Ebina (1996) |
| Ô¤·ÀºÍÖÎÁÆÂÖ×´²¡¶¾ÓÕµ¼µÄСÊó賦Ñ× |
Hatta et al. (1993) |
| ÂÖ×´²¡¶¾¸ÐȾÌåÍâÔ¤·À£ºÊ¹ÓÃIgY¶Ô¿¹ÖØ×éHRVÍâ¿Çµ°°×VP8* |
Kovacs-Nolan et al. (2001) |
| ¹Ú×´²¡¶¾ |
±£»¤ÐÂÉú¶¿Å£ÃâÊÜÅ£¹Ú×´²¡¶¾£¨BCV£©ÒýÆðµÄ¸¹Ðº |
Ikemori et al. (1997) |
| ´ó³¦¸Ë¾ú |
Ô¤·ÀÐÂÉú×ÐÖíK88+¡¢K99+¡¢987P+ETEC¸ÐȾ |
Yokoyama et al. (1992) |
| ±£»¤ÐÂÉú¶¿Å£ÃâÊÜÖÂÃüµÄ³¦µÀ´ó³¦¸Ë¾ú²¡£¨ETEC K99£©µÄÇÖº¦ |
Ikemori et al. (1992) |
| ÒÖÖÆETEC K88¶Ô×ÐÖí³¦ð¤ÒºµÄ𤸽 |
Jin et al. (1998) |
| Ô¤·ÀÐÂÉú¶ùºÍÔç¶ÏÄÌ×ÐÖíETEC K88+¸ÐȾ |
Marquardt et al. (1999) |
| ɳÃÅÊϾú |
±£»¤Ð¡ÊóÃâÊܳ¦Ñ×ɳÃÅÊϾú»òÊóÉ˺®É³ÃÅÊϾúµÄÇÖº¦ |
Yokoyama et al. (1998) |
| Ô¤·À±©Â¶ÓÚÊóÉ˺®É³ÃÅÊϾú»ò¶¼°ØÁÖɳÃÅÊϾúµÄÐÂÉú¶¿Å£·¢ÉúÖÂÃü¸ÐȾ |
Yokoyama et al. (1998) |
| ÒÖÖƳ¦Ñ×ɳÃÅÊϾúÓëÈ˳¦µÀϸ°ûµÄ𤸽 |
Sugita-Konishi et al. (1996) |
| Ò®¶ûÉÊϾú |
±£»¤ºç÷®ÓãÃâÊܳÊÏÒ®¶ûÉÊϾú¸ÐȾ |
Lee et al. (2000) |
| °®µÂ»ª×ÈÊϾú |
Ô¤·À³Ù»º°®µÂ»ªÊϾú¶ÔÈÕ±¾÷©ÓãµÄ¸ÐȾ |
Stevenson et al. (1993) |
| IBDV |
±£»¤³û¼¦ÃâÊÜ´«È¾ÐÔ·¨ÊÏÄÒ²¡¶¾µÄÇÖº¦ |
Gutierrez et al. (1993) |
| ÆÏÌÑÇò¾ú |
ÒÖÖƽð»ÆÉ«ÆÏÌÑÇò¾úAÐͳ¦¶¾ËصIJúÉú |
Sugita-Konishi et al. (1996) |
| ¼Ùµ¥°û¾úÊô |
ÒÖÖÆÂÌŧ¸Ë¾úµÄÉú³¤ |
Sugita-Konishi et al. (1996) |
²Î¿¼ÎÄÏ×
[1]Dias da Silva W, Tambourgi DV. IgY: a promising antibody for use in immunodiagnostic and in immunotherapy. Vet Immunol Immunopathol, 2010, 135(3-4):173-80.
[2]Spillner E, Braren I, Greunke K, et al. Avian IgY antibodies and their recombinant equivalents in research, diagnostics and therapy. Biologicals, 2012, 40(5):313-22.
[3]Pereira EPV, van Tilburg MF, Florean EOPT, et al. Egg yolk antibodies (IgY) and their applications in human and veterinary health: A review. Int Immunopharmacol, 2019, 73:293-303.
[4]Xu Y, Li X, Jin L, et al. Application of chicken egg yolk immunoglobulins in the control of terrestrial and aquatic animal diseases: a review. Biotechnol Adv, 2011,29(6):860-8.
Ïà¹Ø·þÎñ
Ïà¹ØÔĶÁ
ËÕ¹«Íø°²±¸
ËÕICP±¸ºÅ-1
|